To investigate the clinical value of four tumor markers in non-small cell lung cancer

王国洪,万文徽,刘波,刘娟,张书耕,梁震,杨江颖,张晶,董大海
DOI: https://doi.org/10.3760/j:issn:1009-9158.2003.08.012
2003-01-01
Abstract:Objectives To investigate the clinical value of the serum levels of Carcinoembryonic antigen(CEA), Cytokeratin-19-fragments(CYFRA21-1),Tissue Polypeptide Specific Antigen(TPS) and Squamous. Cell Carcinoma Antigen(SCC) in patients with Non-Small Cell Lung Cancer(NSCLC).Methods CEA and CYFRA21-1 were measured by an electrochemiluminescence method with the use of ELECSYS 2010 analyzers. SCC was measured imunoenzymatically, with MEIA methods, using IMx analyzers. TPS was determined by Enzyme-Linked Immunosorbent Assay. 36 Healthy adults and 13 benign pulmonary diseases and 76 patients with non-small cell lung cancer were detected. All data were analyzed by SPSS 10 0 and Receiver Operating Characteristic Curve(ROC). Results The value of CEA,CYFRA21-1 and TPS in the NSCLC,it changed in relationship to stage of disease. There was a significant reference (P0 05) from normal control values. There was a useful clinical reference value to evaluate NSCLC. The sensitivity and effectiveness of the group of CEA+CYFRA21-1+TPS was highest in nine-combined groups. After operation, a marked decrease in these values were observed. It may be used for assessing curative effect after-operation. The level of SCC was demonstrated higher value in squamous cell carcinomas only. Conclusions There was specifically clinical application value of these four tumor markers for diagnosis and cure of NSCLC. The sensitivity and utility can be increased with combination of CEA+CYFRA21-1+TPS in diagnosis of NSCLC.
What problem does this paper attempt to address?